Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
American Journal of Hematology|June 6, 2024
Clinical impact of mutated JAK2 allele burden reduction in polycythemia vera and essential thrombocythemiaPaola Guglielmelli, Barbara Mora, Francesca Gesullo, et al.
Frontiers in Cell and Developmental Biology|April 10, 2024
Chronic myeloproliferative neoplasms with concomitant CALR mutation and BCR::ABL1 translocation: diagnostic and therapeutic implications of a rare hybrid diseaseMagda Zanelli, Valentina Fragliasso, Giuseppe Gaetano Loscocco, et al.
American Journal of Hematology|June 15, 2024
Long-term pharmacodynamic and clinical effects of twice- versus once-daily low-dose aspirin in essential thrombocythemia: The ARES trialBianca Rocca, Alberto Tosetto, Giovanna Petrucci, et al.
Clinical Pharmacology and Therapeutics|November 7, 2021
Association of Platelet Thromboxane Inhibition by Low-Dose Aspirin With Platelet Count and Cytoreductive Therapy in Essential ThrombocythemiaAlberto Tosetto, Bianca Rocca, Giovanna Petrucci, et al.
American Journal of Hematology|November 14, 2019
Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 casesEmanuela Sant'Antonio, Paola Guglielmelli, Lisa Pieri, et al.
The Lancet. Haematology|January 21, 2021
Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trialTiziano Barbui, Alessandro Maria Vannucchi, Valerio De Stefano, et al.
NEJM Evidence|February 6, 2024
Ropeginterferon versus Standard Therapy for Low-Risk Patients with Polycythemia VeraTiziano Barbui, Alessandro Maria Vannucchi, Valerio De Stefano, et al.
Annals of Hematology|December 7, 2023
Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomesTiziano Barbui, Alessandra Carobbio, Valerio De Stefano, et al.
Blood Cancer Journal|March 15, 2018
Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasmsValerio De Stefano, Alessandra Carobbio, Vincenzo Di Lazzaro, et al.
Pageof 2